Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Wheeler, Cosette MCosette MWheelerCastellsagué, XavierXavierCastellsaguéGarland, Suzanne MSuzanne MGarlandSzarewski, AnneAnneSzarewskiPaavonen, JormaJormaPaavonenNaud, PauloPauloNaudSalmerón, JorgeJorgeSalmerónSONG-NAN CHOWApter, DanDanApterKitchener, HenryHenryKitchenerTeixeira, Júlio CJúlio CTeixeiraSkinner, S RachelS RachelSkinnerJaisamrarn, UnnopUnnopJaisamrarnLimson, GenaraGenaraLimsonRomanowski, BarbaraBarbaraRomanowskiAoki, Fred YFred YAokiSchwarz, Tino FTino FSchwarzPoppe, Willy A JWilly A JPoppeBosch, F XavierF XavierBoschHarper, Diane MDiane MHarperHuh, WarnerWarnerHuhHardt, KarinKarinHardtZahaf, ToufikToufikZahafDescamps, DominiqueDominiqueDescampsStruyf, FrankFrankStruyfDubin, GaryGaryDubinLehtinen, MattiMattiLehtinen2023-02-172023-02-172012-011470-2045https://scholars.lib.ntu.edu.tw/handle/123456789/628275We evaluated the efficacy of the human papillomavirus HPV-16/18 AS04-adjuvanted vaccine against non-vaccine oncogenic HPV types in the end-of-study analysis after 4 years of follow-up in PATRICIA (PApilloma TRIal against Cancer In young Adults).enHUMAN-PAPILLOMAVIRUS INFECTION; MAJOR CAPSID PROTEIN; PARTICLE VACCINE; YOUNG-WOMEN; CANCER; NEOPLASIA; EPITOPES; IMPACT; RISK; IDENTIFICATIONCross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialjournal article10.1016/S1470-2045(11)70287-X220751702-s2.0-84855309413WOS:000299014500049https://api.elsevier.com/content/abstract/scopus_id/84855309413